Cannara Biotech Stock Cash And Equivalents
| LOVFF Stock | USD 0.52 0.09 20.93% |
Cannara Biotech fundamentals help investors to digest information that contributes to Cannara Biotech's financial success or failures. It also enables traders to predict the movement of Cannara OTC Stock. The fundamental analysis module provides a way to measure Cannara Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cannara Biotech otc stock.
Cannara |
Cannara Biotech OTC Stock Cash And Equivalents Analysis
Cannara Biotech's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Cannara Biotech Cash And Equivalents | 3.88 M |
Most of Cannara Biotech's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cannara Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Cannara Biotech has 3.88 M in Cash And Equivalents. This is 99.53% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The cash and equivalents for all United States stocks is 99.86% higher than that of the company.
Cannara Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cannara Biotech's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Cannara Biotech could also be used in its relative valuation, which is a method of valuing Cannara Biotech by comparing valuation metrics of similar companies.Cannara Biotech is currently under evaluation in cash and equivalents category among its peers.
Cannara Fundamentals
| Return On Equity | 0.0434 | |||
| Return On Asset | 0.0327 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 94.03 M | |||
| Shares Outstanding | 877.48 M | |||
| Shares Owned By Insiders | 47.54 % | |||
| Price To Earning | 85.00 X | |||
| Price To Book | 1.37 X | |||
| Price To Sales | 1.81 X | |||
| Revenue | 35.84 M | |||
| Gross Profit | 17.33 M | |||
| EBITDA | 8.14 M | |||
| Net Income | 2.31 M | |||
| Cash And Equivalents | 3.88 M | |||
| Total Debt | 46.19 M | |||
| Debt To Equity | 0.49 % | |||
| Current Ratio | 2.13 X | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (6.08 M) | |||
| Earnings Per Share | 0.15 X | |||
| Beta | 1.52 | |||
| Market Capitalization | 63.27 M | |||
| Total Asset | 125.62 M | |||
| Z Score | 0.6 | |||
| Net Asset | 125.62 M |
About Cannara Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cannara Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cannara Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cannara Biotech based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Cannara OTC Stock
Cannara Biotech financial ratios help investors to determine whether Cannara OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cannara with respect to the benefits of owning Cannara Biotech security.